Marinus Pharmaceuticals, Inc
MRNS
MRNS was delisted on the 10th of February, 2025.
80 hedge funds and large institutions have $563M invested in Marinus Pharmaceuticals, Inc in 2021 Q2 according to their latest regulatory filings, with 8 funds opening new positions, 37 increasing their positions, 18 reducing their positions, and 15 closing their positions.
106% more repeat investments, than reductions
Existing positions increased: 37 | Existing positions reduced: 18
67% more funds holding in top 10
Funds holding in top 10: 3 → 5 (+2)
17% more capital invested
Capital invested by funds: $480M → $563M (+$82.9M)
8% less funds holding
Funds holding: 87 → 80 (-7)
27% less call options, than puts
Call options by funds: $6.59M | Put options by funds: $9.01M
47% less first-time investments, than exits
New positions opened: 8 | Existing positions closed: 15
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SAM
Scion Asset Management
Saratoga,
California
|
+$5.27M |
| 2 |
BlackRock
New York
|
+$4.64M |
| 3 |
BL
Bleichroeder LP
New York
|
+$3.74M |
| 4 |
AG
Artal Group
Luxembourg
|
+$3.22M |
| 5 |
Citadel Advisors
Miami,
Florida
|
+$2.99M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Alyeska Investment Group
Chicago,
Illinois
|
-$6.63M |
| 2 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$3.74M |
| 3 |
Adage Capital Partners
Boston,
Massachusetts
|
-$3.22M |
| 4 |
SC
Saltoro Capital
Dallas,
Texas
|
-$1.09M |
| 5 |
JP Morgan Chase
New York
|
-$951K |
MRNS Hedge Fund Activity: Q2 2021 in Review
80 of the 5,745 institutional investors tracked by Wall St. Rank reported a position in Marinus Pharmaceuticals, Inc (MRNS) for Q2 2021, worth a combined $563M — up 17% from $480M a quarter earlier.
Sellers outnumbered buyers: 15 funds closed out of MRNS and 8 opened new positions — a net loss of 7 holders — while 18 trimmed existing stakes and 37 added.
The largest buyer was Scion Asset Management, adding an estimated $5.27M. The largest seller was Alyeska Investment Group, cutting an estimated $6.63M.
- 80 institutional investors held Marinus Pharmaceuticals, Inc (MRNS) as of Q2 2021, down from 87 in Q1 2021.
- Funds reported $563M of Marinus Pharmaceuticals, Inc stock for Q2 2021, up 17% quarter-over-quarter.
- 8 funds opened new Marinus Pharmaceuticals, Inc positions in Q2 2021 and 15 closed out, a net change of -7 holders.
- The largest Marinus Pharmaceuticals, Inc buyer in Q2 2021 was Scion Asset Management, an estimated $5.27M added.
- The largest Marinus Pharmaceuticals, Inc seller in Q2 2021 was Alyeska Investment Group, an estimated $6.63M sold.
Based on aggregated 13F filings for Q2 2021.